Jasmine J Shwetar, Andrea Fava, Sarah Keegan, Philip M Carlucci, Jeffrey N Dudley, Lodoe Lama, Hemant Suryawanshi, Pavel Morozov, Briana J Mullins, Abhimanyu Amarnani, Linda Procell, Dania Annuar, Siddarth Gurajala, Peter M Izmirly, Judith A James, Joel M Guthridge, Thomas M Eisenhaure, Arnon Arazi, Chaim Putterman, Deepak A Rao, Betty Diamond, H Michael Belmont, William Apruzzese, Anne Davidson, Soumya Raychaudhuri, Nir Hacohen, Maria Dall'Era, Cindy Loomis, Robert M Clancy, Thomas Tuschl, Ming Wu, Derek M Fine, Mohamed G Atta, Jose Monroy-Trujillo, Richard Furie, Diane L Kamen, Kenneth Kalunian, Accelerating Medicine Partnership in RA/SLE, Michelle Petri, Jill P Buyon, Brad H Rovin, Kelly V Ruggles
Class II LN harbors substantial molecular activity not captured by routine histology. Fibroblast transcriptional programs and baseline chronicity index are candidate correlates of kidney outcome that warrant validation in larger, prospectively followed cohorts.
INTRODUCTION: Class II lupus nephritis (LN) is considered clinically benign, yet up to 50% of patients progress to more severe disease and no molecular characterization exists. We aimed to define the single-cell landscape of Class II LN and identify cellular and transcriptional features associated with kidney outcome.
METHODS: We performed single-cell RNA sequencing on kidney biopsies from fifteen Class II LN patients (eight de novo, seven regressed from prior proliferative or membranous disease) and six healthy controls, integrated with 155 LN and 30 healthy-control samples from the Accelerating Medicines Partnership in SLE spanning proliferative, membranous, and mixed LN. Findings were correlated with 52-week renal response and supported by urinary proteomics.
RESULTS: Despite histologically minimal changes, Class II LN exhibited marked immune cell expansion comparable to proliferative and membranous LN, including CCL3+ CCL4+ intermediate monocytes producing TNF, FOLR2+ SIGLEC1+ macrophages producing TGFβ and PDGF, and CD69+ CD8+ effector memory T cells producing IFNγ. Fibroblasts and myofibroblasts were significantly expanded and displayed divergent transcriptional programs: pro-fibrotic and inflammatory myofibroblast modules were associated with worse 52-week outcomes, while interferon-responsive and matrix-remodeling fibroblast programs were associated with improvement. Pathogenic and protective fibroblast populations received overlapping immune-derived signals, suggesting that fibroblast transcriptional state, rather than the identity of incoming signals, shapes the stromal response. Baseline chronicity index captured this stromal heterogeneity and was the clinical parameter most associated with outcome. Urinary proteomics aligned Class II with proliferative rather than membranous disease.
CONCLUSIONS: Class II LN harbors substantial molecular activity not captured by routine histology. Fibroblast transcriptional programs and baseline chronicity index are candidate correlates of kidney outcome that warrant validation in larger, prospectively followed cohorts.